Navigation Links
MDS Announces Formation of Special Committee
Date:2/2/2009

TORONTO, Feb. 2 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life-sciences markets, today announced that it has constituted a committee of independent directors to support the Company's continuing process of reviewing alternatives to improve shareholder value. With the assistance of management and advisors, the Board of Directors continuously reviews the performance of MDS, and looks for options to improve returns to shareholders, including an annual strategic review. The Board has determined that constituting a committee to work closely with management and the company's advisors is now appropriate.

The committee is comprised of William Anderson, Robert Luba, James MacDonald and Gregory Spivy, each of whom is independent of management. James MacDonald will act as Chair of the committee. Goldman, Sachs & Co and RBC Capital Markets are assisting the Company and the Board of Directors as financial advisors. The focus of the review is on assessing strategic alternatives. MDS emphasized that there can be no assurance that this process will result in any specific strategic or financial transaction - especially given the uncertain market and economic conditions. No timetable has been set for its completion.

Caution Concerning Forward-Looking Statements

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates" or similar expressions. The statements are not a guarantee of future performance and are inherently subject to risks and uncertainties. MDS's actual results could differ materially from those expressed in the forward-looking statements due to these risks and a number of other factors, including, but not limited to, successful implementation of structural changes, including restructuring plans and acquisitions, technical or manufacturing or distribution issues, the competitive environment for MDS's products and services, the degree of market penetration of its products and services, the ability to secure a reliable supply of raw materials, the impact of our clients' exercising rights to delay or cancel certain contracts, the strength of the global economy, the stability of global equity markets, the availability and cost of financing, the impact of the movement of the U.S. dollar relative to other currencies, particularly the Canadian dollar and the euro, uncertainties associated with critical accounting assumptions and estimates, and other factors set forth in reports and other documents filed by MDS with Canadian and U.S. securities regulatory authorities from time to time, including MDS's quarterly and annual MD&A, annual information form, and annual report on Form 40-F for the fiscal year ended October 31, 2008 filed with the U.S. Securities & Exchange Commission.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes
2. Metoprolol Succinate Recalled: Brand Name Drug Scarce But Still Available at Low Cost from Other Countries, PharmacyChecker.com Announces
3. Smith & Nephew Announces Agreement with the OREF Regarding Grants to Support Research and Education in Orthopaedics
4. Meijer Announces Voluntary Recall for Some Meijer Brand Peanuts and Ice Cream Novelties Citing Possible Health Risk
5. Medco Announces Date for Fourth-Quarter and Full-Year 2008 Financial Results
6. Lilly Announces Senior Leadership Change
7. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
8. QLT announces final results of tender offer
9. ePharmaceuticals™ Announces the Launch of epharmcomply.com
10. Accuray Announces Results for Second Quarter of Fiscal 2009
11. First Coast Service Options Announces Start up of New Medicare Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/25/2017)... ... 25, 2017 , ... FCPX users now have the ability to sharpen a ... ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, ... spectrum tools users can visually see the color range effected with ease all within ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Only two ... International Luxury Travel Market (ILTM) show in Cannes (France), XO Private has initiated a ... tome, the 420-page book measures almost a metre across when open, weighs in at ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provost of Liberty University, has officially announced the appointment of Peter A. Bell, ... College of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ... is so critically important that we all are aware of our options and ... is proud to announce the launch of its newest edition of "Vision and ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 24, 2017 ... Monteverde & Associates PC , a boutique securities firm ... New York City , announces that a class ... Massachusetts  against Inotek Pharmaceuticals Corporation ... of the Company,s securities between July 23, 2015 and December ...
(Date:2/24/2017)...  Directors from Pharma To Market Pty Ltd and Ador Consulting ... in the founding of Pharma To Market Pte Ltd, based in ... pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia , ... Singapore based entity. Joelle brings with her an extensive ...
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
Breaking Medicine Technology: